ARK Genomic Revolution ETF
ARKG ThematicUpdated: Jul 5, 2026, 21:17 UTC
Key Metrics
Top 10 Holdings
| Holding | Ticker | Weight | Bar |
|---|---|---|---|
| Twist Bioscience Corp | TWST | 8.56% | |
| CRISPR Therapeutics AG | CRSP | 8.22% | |
| Tempus AI Inc Class A common stock | TEM | 7.78% | |
| Personalis Inc | PSNL | 6.4% | |
| 10x Genomics Inc Ordinary Shares - Class A | TXG | 6.29% | |
| Absci Corp | ABSI | 5.63% | |
| Beam Therapeutics Inc | BEAM | 5.07% | |
| Guardant Health Inc | GH | 4.51% | |
| Illumina Inc | ILMN | 4.48% | |
| Natera Inc | NTRA | 4.11% |
Sector Allocation
About This ETF
The ARK Genomic Revolution ETF (ARKG) is a Thematic ETF with an expense ratio (TER) of 0.75% and $1.3B in assets under management., with its largest holdings being Twist Bioscience Corp, CRISPR Therapeutics AG, Tempus AI Inc Class A common stock. Year-to-date, ARKG has returned +47.05%.
The fund is an actively-managed exchange-traded fund ("ETF") that will invest under normal circumstances primarily (at least 80% of its assets) in domestic and foreign equity securities of companies across multiple sectors, including healthcare, information technology, materials, energy and consumer discretionary, that are relevant to the fund's investment theme of the genomics revolution ("Genomics Revolution Companies"). It is non-diversified.
FAQ — ARKG
What is the TER of ARKG (ARK Genomic Revolution ETF)?
ARKG has a Total Expense Ratio (TER) of 0.75 % per year. That sits above the thematic category median (0.68 % across 15 peer ETFs). The TER is deducted directly from the fund and lowers your effective return.
What return has ARKG delivered?
Performance for ARKG: YTD: +47.05 % · 3-year p.a.: +8.10 % · 5-year p.a.: -14.04 %. Over 5 years, ARKG underperforms the thematic category median of +2.05 % by -16.09 pp. Past performance is no guarantee of future returns.
What are the top holdings of ARKG?
The five largest positions in ARKG are: TWST, CRSP, TEM, PSNL, TXG. The full holdings list is updated daily on this page.
Where can I buy or set up a savings plan for ARKG?
ARKG is available at most major brokers. For a free monthly savings plan from €1, look at Trade Republic, Scalable Capital or Flatex. The broker comparison on this site shows fees, free-savings-plan ETFs and execution exchanges side by side.
ARK Genomic Revolution ETF (ARKG): active bets on the genomics revolution
The ARK Genomic Revolution ETF is an actively managed thematic fund from ARK that targets companies in genomics, biotech and healthcare innovation. Its largest positions include Tempus AI (9.45%), Twist Bioscience (9.02%) and CRISPR Therapeutics (8.94%). With an expense ratio of 0.75% and roughly $1.2B in assets, it concentrates forward-looking single-stock bets within one of the market's most volatile segments.
Performance: a sharp rebound after a deep slump
The return figures highlight just how wide this thematic fund's swings can be. Year to date, the ARK Genomic Revolution ETF is up +16.93%, and at $34.12 the price sits close to its 52-week high of $34.39 (98.1% of the range). The longer-term picture, however, tells a different story: the annualized 3-year return is a meagre +0.39%, while the 5-year return stands at −16.88% per year. The 52-week low of $20.46 underscores how far the price had fallen in the interim. The fund pays no dividend (0.0% yield), so total return depends almost entirely on price appreciation in individual innovation stocks.
Risk profile: extreme volatility and deep drawdowns
The ARK Genomic Revolution ETF is among the most volatile building blocks on the market. It is classified as non-diversified and is 100% invested in the healthcare sector, with its ten largest positions accounting for a substantial share of assets. Young biotech and genomics firms such as Beam Therapeutics or Intellia Therapeutics are often not yet profitable and react sharply to interest rates, trial results and regulation. The negative 5-year return of −16.88% per year and the wide 52-week range from $20.46 to $34.39 show the scale of possible drawdowns. There is also manager risk: outcomes depend heavily on the ARK team's active selection decisions.
Which investors might it be intended for?
This thematic fund is aimed at investors with a very long horizon, a high tolerance for risk and the nerve to withstand double-digit or larger price declines. Those who believe in the long-term potential of gene sequencing, CRISPR therapies and precision medicine, and who trust an active management philosophy, might consider ARKG as a small, satellite-style allocation. The high 0.75% expense ratio, the concentration in a single sector and the absence of a dividend (0.0%) argue against using it as a core holding. For safety-oriented profiles or short time horizons, the product appears poorly suited given its swings. This is not investment advice.
Competitors: genomics and biotech alternatives
The peer group includes several biotech and genomics products with different approaches:
- iShares Biotechnology ETF (IBB): broad, index-based exposure to the biotech sector, including large, established companies.
- SPDR S&P Biotech ETF (XBI): an equal-weighted index with a strong tilt toward smaller biotech names and correspondingly high volatility.
- ARK Innovation ETF (ARKK): another actively managed ARK fund, but spread more broadly across several innovation themes.
The key difference: ARKG is active, highly concentrated and manager-dependent, whereas IBB and XBI track an index on a rules-based basis and are usually cheaper than ARKG's 0.75% expense ratio.
Where can I buy ARKG?
Compare the best brokers for ETF savings plans — low fees, trusted providers, fully regulated.